Adagene (FRA:978) FFO


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.48
GF Value €11.94
! 5 Warning Signs
View Full Analysis

What is Adagene FFO?

FFO (Funds from operations) only applies to REITs.

FRA:978
42GF Score
Adagene Inc FRA:978
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.48 is trading 70.9% below its estimated GF Value™ of €11.94.

Key valuation signals for FRA:978:

  • FFO:
  • GF Value™: €11.94 vs. price of €3.48 (70.9% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price
€11.94
GF Value